03/22/23 4:30 PMNasdaq : IVVD covid-19Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19Research published online today in peer-reviewed journal Science Translational Medicine Analysis of data from a Phase 2/3 COVID-19 prevention study (EVADE) of adintrevimab suggests clinically meaningful protection can be achieved at low neutralizing antibody titers Work builds on vaccine studiesRHEA-AInegative
03/16/23 7:00 AMNasdaq : IVVD conferencesearningsInvivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business HighlightsInvivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 23, 2023, at 4:30 p.m.RHEA-AIneutral
03/06/23 7:00 AMNasdaq : IVVD covid-19Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal AntibodiesCompany seeks to utilize emerging global COVID-19 regulatory frameworks to accelerate development of VYD222 and its pipeline of other candidates VYD222 mAb candidate has demonstrated in vitro neutralizing activity against dominant variants of concern, including XBB.1.5 Invivyd maintains guidanceRHEA-AIneutral
03/01/23 4:15 PMNasdaq : IVVD Investors purchased NASDAQ: IVVD shares between November 29 and December 14, 2021, should contact the Shareholders Foundation in connection with the Lawsuit against Invivyd, Inc.The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in of Invivyd, Inc. (NASDAQ:IVVD) shares over alleged securities laws violations by Invivyd, Inc. f.k.a. Adagio Therapeutics, Inc. Investors, who purchased sharesRHEA-AIvery negative
02/28/23 7:00 AMNasdaq : IVVD conferencesInvivyd to Participate at Cowen’s 43rd Annual Healthcare ConferenceInvivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to present at Cowen’sRHEA-AIneutral
02/03/23 7:30 AMNasdaq : IVVD Invivyd Announces Changes to Executive TeamInvivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company’s chief scientific officer and co-founder, decided toRHEA-AIneutral
12/19/22 7:00 AMNasdaq : IVVD Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopInvivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held onRHEA-AIneutral
12/06/22 4:01 PMNasdaq : IVVD managementInvivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical OfficerInvivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer,RHEA-AIneutral
11/17/22 7:00 AMNasdaq : IVVD partnershipclinical trialcovid-19Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond- - Population Health Partners to integrate best-in-class capabilities to drive speed andRHEA-AIneutral
11/10/22 4:01 PMNasdaq : IVVD earningsInvivyd Reports Third Quarter 2022 Financial Results and Business HighlightsNovel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10 th at 4:30 p.m. ETRHEA-AIneutral